fludarabine + dexamethasone

Fludarabine + dexamethasone is a combination of two pharmaceutical agents commonly used in hematologic malignancies, particularly for the treatment of chronic lymphocytic leukemia (CLL) and other lymphoid cancers. Fludarabine is an antimetabolite chemotherapy agent that inhibits DNA synthesis by targeting DNA polymerase alpha, ribonucleotide reductase, and DNA primase, leading to cell death in rapidly dividing cancer cells[1][5][8]. Dexamethasone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties; it acts primarily through glucocorticoid receptor agonism to modulate gene expression and suppress immune responses[3]. The combination may be used as part of multi-drug regimens for enhanced anti-cancer efficacy or to manage side effects such as inflammation or immune-mediated complications.

Other names

fludarabine phosphate